人免疫缺陷病毒感染患者的肺动脉高压。
Pulmonary Arterial Hypertension in Patients Infected with the Human Immunodeficiency Virus.
机构信息
Division of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, 800 Washington Street, Box 257, Boston, MA 02111, USA.
Division of Infectious Diseases, University of Rochester Medical Center, 601 Elmwood Avenue, Box 689, Rochester, NY 14642, USA.
出版信息
Cardiol Clin. 2022 Feb;40(1):45-54. doi: 10.1016/j.ccl.2021.08.004.
It is important to recognize and treat human immunodeficiency virus-associated pulmonary arterial hypertension (HIV-PAH) because of the associated morbidity and mortality. With the introduction of antiretroviral therapies (ART), improved survival has changed the focus of treatment management from immunodeficiency-related opportunistic infections to chronic cardiovascular complications, including HIV-PAH. The 2018 6th World Symposium of Pulmonary Hypertension recommended a revised definition of PAH that might result in a greater number of patients with HIV-PAH; however, the implication of this change is not yet clear. Here, we review the current literature on the diagnosis, management, and outcomes of patients with HIV-PAH.
认识和治疗与人类免疫缺陷病毒相关的肺动脉高压（HIV-PAH）非常重要，因为它与发病率和死亡率相关。随着抗逆转录病毒疗法（ART）的引入，生存的改善已经改变了治疗管理的重点，从与免疫缺陷相关的机会性感染转移到包括 HIV-PAH 在内的慢性心血管并发症。2018 年第六届世界肺动脉高压研讨会推荐了肺动脉高压的修订定义，这可能导致更多的 HIV-PAH 患者；然而，这一变化的影响尚不清楚。在这里，我们回顾了关于 HIV-PAH 患者的诊断、管理和结局的现有文献。
Zotero 插件